carcinoma prostate second common cancer men spite aggressive therapies control metastatic prostate cancer remains elusive objective patients die secondary disease targeted emerging therapeutic modality labeled protein selectively targets cancer cells delivers lethal payload kill cancer cells transit preangiogenic cell clusters recent studies targeted highly cytotoxic prostate cancer cells vitro inhibit tumor growth animal models review consider radionuclides current vitro vivo studies focus target antigens targeting vectors treatment prostate cancer references NUMBER alpha therapy alpha therapy alpha emitting alpha radioconjugates cell surface